QUEBEC CITY, May 8, 2014 /CNW Telbec/ - Opsens Inc. ("Opsens" or "the Company") (TSX-V: OPS) today announced that it has appointed Lucien Goffart as a Member of the Board of Directors. The appointment of Mr. Goffart, an international sales and marketing specialist in interventional cardiology devices, shows that Opsens is highly committed to breaking into the Fractional Flow Reserve ("FFR") market.
Goffart said "I am honored and delighted to get on board with Opsens' exciting products that are about to enter the fast-growing FFR market. I look forward to working with the Company's dedicated team to bring Opsens' FFR products to cardiologists."
Goffart, who holds a degree in international trade and a Master in Business, started his career in 1999 with Johnson & Johnson Inc. He moved on to Abbott Laboratories, Limited and then joined Volcano Europe BVBA/SPRL, where he worked from 2004 to 2011. He recently worked with STENTYS SA, a company marketing interventional cardiology devices and is currently General Manager for Mitralign, a medical device company that developed a mitral-valve repair therapy, a unique system that provides a new solution for interventional cardiologists and their patients.
Opsens' President and CEO, Louis Laflamme said, "Lucien is a well-known and respected marketing specialist with vast experience in the commercialization of medical devices that target interventional cardiologists. We look forward to working with him to enhance awareness of Opsens' FFR products and to prepare for their entry into the market beginning in early 2015. The FFR market was estimated at US$250 million in 2013 and is growing at a rate of 15-17% annually."
"The Board is pleased to welcome Lucien. His arrival will improve Opsens' expertise and governance to meet the expectations of our shareholders," said Pierre Carrier, Chairman of the Board of Directors.
GRANT OF STOCK OPTIONS
Opsens' Board of Directors authorized the grant of 100,000 stock options to Lucien Goffart, as provided in the Company's stock option plan adopted by the shareholders on January 20, 2014.
Under the provisions of Opsens' stock option plan, each stock option granted entitles the holder to subscribe to one Opsens common share by May 6, 2019 and at a price equal to $0.75 per share. The stock options have no vesting period.
About Opsens Inc. (www.opsens.com)
Focusing on two main growth markets, FFR in medical instrumentation and oil and gas, Opsens develops, manufactures and installs systems to measure pressure and temperature as well as other parameters using fiber optic sensing technologies. These systems are designed around patented technologies that are effective and durable in extreme conditions.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: OPSENS INC.
For further information: Thierry Dumas, CPA, CA, Chief Financial Officer, 418.682.9996; Louis Laflamme, CPA, CA, Chief Executive Officer, 418.682.9996